Uncategorized

Investor’s Alert: Redfin Corporation (NASDAQ:RDFN) & Cytokinetics, Incorporated (NASDAQ:CYTK)

Redfin Corporation (NASDAQ:RDFN)

Redfin Corporation is engaged in providing residential real estate search and brokerage services. The Company provides an online real estate marketplace and provides real estate services, such as assisting individuals to purchase or sell their residential property. It also provides title and settlement services and originate mortgages. Redfin Corporation is headquartered in Seattle, Washington.

Redfin Corporation (NASDAQ:RDFN)’s Financial Overview

Redfin Corporation (NASDAQ) declined -0.11% yesterday to close its trading session at $18.12. The company has 1 year Price Target of $17. Redfin Corporation has 52-Week high of $26.01 and 52-Week Low of $13.5. The stock touched its 52-Week High on 26.01 and 52-Week Low on 13.50. The stock traded with the volume of 626212 shares yesterday. The firm shows the market capitalization of $1.59 Billion.

Redfin Corporation (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.04/share against the analyst consensus estimate of $0.02/share. The difference between the actual and expected EPS is $0.02 a share with a surprise factor of 100%.

The firm is trading with SMA20 of 4.09 Percent, SMA50 of 10.39 Percent and SMA200 of -5.67 percent. Redfin Corporation has P/S value of 3.46 while its P/B value stands at 4.26. Similarly, the company has Return on Assets of -9 percent, Return on Equity of -12.1 percent and Return on Investment of -12.1 Percent. The company shows Gross Margin and Operating Margin of 26.7 percent and -7.4 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 2.8 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 13 analysts offering 12-month price forecasts for Redfin Corp have a median target of 16.00, with a high estimate of 21.00 and a low estimate of 12.00. The median estimate represents a -11.70% decrease from the last price of 18.12.

Redfin Corporation is expected* to report earnings on 02/14/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.02.

Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.

Cytokinetics, Incorporated (NASDAQ:CYTK)’s Financial Outlook

The 6 analysts offering 12-month price forecasts for Cytokinetics Inc have a median target of 12.50, with a high estimate of 21.00 and a low estimate of 10.00. The median estimate represents a +69.61% increase from the last price of 7.37.

Cytokinetics, Incorporated is expected* to report earnings on 02/21/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.55. The reported EPS for the same quarter last year was $-0.75.

According to Zacks Investment Research, Cytokinetics, Incorporated has a Consensus Recommendation of 1.5. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 4.54% and closed its last trading session at $7.37. The company has the market capitalization of $403.21 Million. The stock has 52-week high of $10 and 52-Week low of $5.9. The firm touched its 52-Week high on 10.00 and 52-Week low on 5.90. The company has volume of 321778 shares. The company has a total of 54.71 Million shares outstanding.

Cytokinetics, Incorporated (NASDAQ) in the last quarter reported its actual EPS of $-0.4/share where the analyst estimated EPS was $-0.51/share. The difference between the actual and Estimated EPS is $0.11. This shows a surprise factor of 21.6 percent.

The company has YTD performance of 16.61 percent. Beta for Cytokinetics, Incorporated stands at 2.06 while its ATR (average true range) is 0.37. The company has Weekly Volatility of 5.45%% and Monthly Volatility of 4.59%%.

Cytokinetics, Incorporated has distance from 20-day Simple Moving Average (SMA20) of 4.97%, Distance from 50-Day Simple Moving Average of 3.45 percent and Distance from 200-Day Simple Moving Average of -5.91%.

The Company currently has ROA (Return on Assets) of 0 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of -80.1% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.